Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TC-5214 adjunctive to SSRI/SNRI in major depressive disorder with inadequate antidepressant response
2010-019925-33Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing TC-5214 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Change in MADRS total score. Started Jun 2010; status: completed.
02
Drugs
dexmecamylamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-019925-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019925-33.